A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

NCT06911788 | Completed Phase 1

• 2 other identifiers: C48910372024-518134-92-00
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to learn how much of the study medicine called Vepdegestrant will reach the bloodstream when given orally compared to given intravenously. This study is seeking participants who:

• are healthy males and healthy females who cannot have children.
• are 18 years or older.
• are healthy as decided by medical tests.
• have a body mass index (BMI) of 16 to 32 kilogram per meter squared.
• have a total body weight of more than 45 kilograms (99 pounds). In Period 1, all participants will receive one dose of Vepdegestrant by IV. In Period 2, all participants will receive one dose of Vepdegestrant by mouth following a high-fat breakfast. The levels of Vepdegestrant in Period 1 will be compared to the levels of Vepdegestrant in Period 2 and the bioavailablility of the oral formulation of Vepdegestrant will be determined. The study duration is 22 days and includes two periods. Participants will stay in the clinical research unit for 9 days (8 nights) during each period. A follow-up visit for each participant takes place at 28 to 35 days after taking the study medicine for the last time.

Conditions

Healthy Participants

Outcome Measures

Primary Outcomes (2)

• Dose-normalized (dn) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant after oral administration

  dn AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) divided by dose. It is obtained from AUC (0 - t) plus AUC (t - ∞).

  At predefined intervals throughout the treatment period, up to approximately 1 week after the last dose of Vepdegestrant

• Dose-normalized (dn) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant after IV administration

  dn AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

  At predefined intervals throughout the treatment period, up to approximately 1 week after the last dose of Vepdegestrant

Secondary Outcomes (4)

• Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

  First dose of Vepdegestrant through 35 days after last dose Vepdegestrant

• Number of Participants With Clinical Laboratory Abnormalities

  First dose of Vepdegestrant through 35 days after last dose Vepdegestrant

• Number of Participants With Clinically Significant Change From Baseline in Vital Signs

  First dose of Vepdegestrant through 35 days after last dose Vepdegestrant

• Number of Participants With Electrocardiogram (ECG) Abnormalities

  First dose of Vepdegestrant through 35 days after last dose Vepdegestrant

Study Arms (1)

Vepdegestrant oral and IV administration

EXPERIMENTAL

Participants will receive a single IV infusion of Vepdegestrant on Day 1 of Period 1 followed by a single 200 mg dose of Vepdegestrant registrational tablet on Day 1 of Period 2.

Drug: Vepdegestrant (Reference); Drug: Vepdegestrant (Test)

Interventions

Vepdegestrant (Reference) DRUG

Participants will receive a single intravenous (IV) dose of Vepdegestrant on Period 1 Day 1

Also known as: ARV-471, PF-07850327

Vepdegestrant oral and IV administration

Vepdegestrant (Test) DRUG

Participants will receive a 200 mg single oral dose of Vepdegestrant tablet formulation on Period 2 Day 1

Also known as: ARV-471, PF-07850327

Vepdegestrant oral and IV administration

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male participants, and/or female participants of non-childbearing potential who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
• Body mass index (BMI) of 16-32 kg/m2; and a total body weight \>45 kg (99 lb).

You may not qualify if:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
• Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy)
• History of or positive testing for HIV infection, hepatitis B, or hepatitis C.
• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Use of prescription or nonprescription drugs and dietary and herbal supplements, grapefruit/grapefruit containing products, and Seville orange/Seville orange containing products within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
• Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
• A positive urine drug test
• Screening blood pressure ≥140/90 mm Hg for participants \<60 years; and ≥150/90 mm Hg for participants ≥60 years old.
• Renal impairment as defined by an eGFR in adults \<60 mL/min/1.73 m² based on CKD-EPI equation.
• Standard 12 lead electrocardiogram that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QTcF \>450 ms, complete left bundle branch block, signs of a myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias).
• History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
• months prior or current use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Sponsors & Collaborators

• Pfizer: lead
• Arvinas Estrogen Receptor, Inc.: collaborator

Study Sites (2)

ICON

Groningen, 9728 NZ, Netherlands

Location

ICON - screening centre

Utrecht, 3584 BL, Netherlands

Location

Related Links

• To obtain contact information for a study center near you, click here.

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 28, 2025
• First Posted: April 4, 2025
• Study Start: April 3, 2025
• Primary Completion: May 23, 2025
• Study Completion: June 13, 2025
• Last Updated: June 29, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

NL (2)